France Debates Doliprane Sale Amid Sovereignty Concerns

The French government scrutinizes Sanofi's potential sale of its Opella unit to a U.S. firm, citing national security and employment concerns.

Sanofi plans to sell a 50% stake in its consumer health division, Opella, to American investment firm Clayton, Dubilier & Rice, raising fears over French economic sovereignty.
The French government is considering taking a stake in Opella and has demanded commitments to maintain production and jobs in France.
Economic and political figures criticize the sale as a failure of France's industrial policy, highlighting the government's previous commitments to relocalize pharmaceutical production.
Sanofi defends the sale, emphasizing its intention to focus on innovative medicines and maintaining a significant stake to ensure strategic influence.
Trade unions and local employees express concerns over potential job losses and the implications for France's pharmaceutical independence.